{"nctId":"NCT02516657","briefTitle":"Liraglutide in Adolescents With Type 1 Diabetes","startDateStruct":{"date":"2012-05","type":"ACTUAL"},"conditions":["Type 1 Diabetes"],"count":5,"armGroups":[{"label":"Liraglutide 0.6 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Liraglutide"]}],"interventions":[{"name":"Liraglutide","otherNames":["Victoza"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosis of Type 1 Diabetes Mellitus greater than 1 year\n* Insulin regimen - continuous subcutaneous insulin infusion with continuous glucose monitoring device\n* HbA1c \\<10%\n\nExclusion Criteria:\n\n* Previous exposure to liraglutide\n* History of abdominal surgery\n* Gastrointestinal reflux disease\n* History of acute or chronic pancreatitis\n* History of alcohol abuse or unwillingness to abstain from alcohol during the study\n* History of thyroid cancer\n* Family history of Multiple Endocrine Neoplasia 2B syndrome\n* Pregnant/breastfeeding females\n* Individuals with antibody-negative insulin requiring diabetes that is consistent with Monogenic Diabetes of Youth\n* Individuals with steroid induced or cystic fibrosis related diabetes","healthyVolunteers":false,"sex":"ALL","minimumAge":"15 Years","maximumAge":"21 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Mean Weekly Blood Glucose","description":"The primary outcome is to determine whether liraglutide decreases mean weekly blood glucose (mean mg/dL glucose as measured by continuous glucose monitor readings) in adolescents with Type 1 diabetes","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"187","spread":"35"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"178","spread":"42"}]}]}]},{"type":"SECONDARY","title":"Total Daily Insulin Dose","description":"mean U/kg/day over 7 days","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.97","spread":"0.18"},{"groupId":"OG001","value":"0.67","spread":"0.14"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Blood Sugar < 70 mg/dL","description":"Determine whether liraglutide increases episodes of blood sugar \\<70 mg/dL as measured by glucometer and CGM","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.5","spread":"7.7"},{"groupId":"OG001","value":"3.3","spread":"3.3"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Serum Amylase Level","description":"Determine amylase levels before and during liraglutide treatment","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":"15"},{"groupId":"OG001","value":"33","spread":"11"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":5},"commonTop":[]}}}